Nicotinic acid: clinical considerations

Expert Opinion on Drug Safety
Anastazia Kei, Moses S Elisaf

Abstract

Nicotinic acid (NA), the oldest hypolipidemic drug, possesses unique broad-spectrum beneficial effects on lipid profiles. Specifically, NA reduces both triglycerides and low-density lipoprotein cholesterol levels, while significantly increasing high-density lipoprotein cholesterol levels. However, NA is often avoided in the clinical setting, or prematurely discontinued by the provider or patient, due to side effects that could possibly be prevented (flushing, gastrointestinal disorders) or that are feared out of proportion to their true incidence rate (hyperglycemia, hyperuricemia). This article reviews NA's side effects, along with a number of old and new strategies to reduce their incidence, especially flushing. The aim of this paper is to provide a useful clinical guide to the administration of NA in dyslipidemic patients. An important number of side effects affects compliance and restricts NA's clinical use. NA-induced flushing is the most restricting side effect, accounting for the majority of NA therapy discontinuations. In addition, gastrointestinal side effects, hyperuricemia, deterioration of glycemic profile, or even new-onset diabetes discourage therapy consecution. Aspirin pretreatment, considered selection and prop...Continue Reading

Associated Clinical Trials

References

Jul 1, 1991·Clinical Pharmacology and Therapeutics·R H SternA Parbtani
Jan 1, 1991·European Journal of Clinical Pharmacology·K G Berge, P L Canner
Apr 1, 1991·Baillière's Clinical Rheumatology·J T Scott
Dec 19, 1990·JAMA : the Journal of the American Medical Association·L Cashin-HemphillD H Blankenhorn
Nov 11, 1988·The American Journal of Cardiology·J A Tobert
Dec 1, 1986·Journal of the American College of Cardiology·P L CannerW Friedewald
Oct 1, 1995·The American Journal of Medicine·L W GibbonsS Grundy
Aug 1, 1995·American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists·W R Garnett
Jan 1, 1994·Dermatology : International Journal for Clinical and Investigative Dermatology·H StalsM A Morren
Nov 5, 1997·Journal of General Internal Medicine·P W JungnickelJ R Campbell
Jan 23, 1999·The American Journal of Cardiology·D M CapuzziJ Brody
May 26, 2001·The American Journal of Cardiology·R H Knopp
Jan 5, 2002·The New England Journal of Medicine·B G BrownJ J Albers
Jul 1, 1995·American Journal of Therapeutics·Raymond T. DunnFabia A. Kwiecinski
Jan 11, 2003·The Journal of Biological Chemistry·Alan WiseNicholas B Pike
Feb 4, 2003·Nature Medicine·Sorin TunaruStefan Offermanns
Mar 14, 2003·The American Journal of Cardiology·Harold E BaysUNKNOWN ADvicor Versus Other Cholesterol-Modulating Agents Trial Evaluation
Mar 21, 2003·Biochemical and Biophysical Research Communications·Takatoshi SogaKiyoshi Furuichi
Jun 7, 2003·American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists·James McKenney
Aug 26, 1961·JAMA : the Journal of the American Medical Association·N A CHRISTENSENH L MASON
Dec 18, 2003·Annals of Internal Medicine·C Daniel MeyersJohn D Brunzell
May 28, 2004·Expert Opinion on Pharmacotherapy·John R Guyton
Jul 20, 2004·Journal of Lipid Research·Shobha H GanjiMoti L Kashyap
Jul 28, 2004·The American Journal of Cardiology·Melvyn Rubenfire, UNKNOWN Impact of Medical Subspecialty on Patient Compliance to Treatment Study Group
Jan 12, 2005·The American Journal of Cardiology·Paul L CannerMark E McGovern
May 14, 2005·Current Opinion in Lipidology·Rudolf ZechnerRobert Zimmermann
Jul 16, 2005·Journal of Internal Medicine·L A Carlson
Dec 3, 2005·The Journal of Clinical Investigation·Zoltán BenyóStefan Offermanns
Feb 10, 2006·Current Medical Research and Opinion·A VogtUNKNOWN NAUTILUS Study Group
Apr 18, 2006·Proceedings of the National Academy of Sciences of the United States of America·Kang ChengM Gerard Waters
Jun 30, 2006·International Journal of Clinical Practice·H Oberwittler, M Baccara-Dinet

❮ Previous
Next ❯

Citations

Jul 22, 2014·Alcoholism, Clinical and Experimental Research·Kusum K Kharbanda
Apr 24, 2014·Diabetes Care·Helen L BarrettLeonie K Callaway
Aug 9, 2016·Rheumatology·C Ben SalemHoussem Hmouda

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.